To revise the standards of PET imaging in neurodegenerative disorders with dementia and/or parkinsonism, with a specific focus on practical issues related to image procedures and interpretation.
Key Findings:
PET imaging allows for early detection of neurodegenerative diseases by visualizing specific molecular pathologies.
Amyloid PET can identify preclinical Alzheimer's disease years before symptoms appear, facilitating early intervention.
Tau PET may track disease progression more closely than amyloid imaging, providing insights into neurodegeneration.
FDG-PET detects subtle brain function changes before structural changes are visible on MRI, aiding in early diagnosis.
Interpretation:
PET imaging biomarkers are essential for early diagnosis and monitoring of neurodegenerative diseases, facilitating the development of new therapies aimed at modifying disease progression.
Limitations:
Imaging performance and interpretation details are often unfamiliar to prescribers and practitioners, leading to potential misinterpretations.
Amyloid PET does not correlate with the degree of cognitive impairment, which can complicate clinical decisions.
Conclusion:
PET imaging represents a significant advancement in the biological understanding and clinical management of neurodegenerative disorders, with implications for early diagnosis and treatment strategies.
